Fig. 4.

a Greatest percent change from baseline per patient at any time during the study in vascular endothelial growth factor (VEGF) and soluble VEGF receptor 2 (sVEGFR2) in patients with high (≥mAUC_ss-cycle1) and low (<mAUC_ss-cycle1) exposure to axitinib, and b proportion of patients with investigator-assessed partial responses in quartiles grouped according to change from baseline in soluble proteins. mAUC_ss-cycle1, median area under the plasma concentration–time curve at steady-state during cycle 1